The stock of Loxo Oncology Inc (NASDAQ:LOXO) is a huge mover today! The stock decreased 8.52% or $2.23 during the last trading session, hitting $23.95. About 177,277 shares traded hands or 160.14% up from the average. Loxo Oncology Inc (NASDAQ:LOXO) has risen 39.33% since February 29, 2016 and is uptrending. It has outperformed by 27.11% the S&P500.
The move comes after 6 months negative chart setup for the $533.32 million company. It was reported on Oct, 4 by Barchart.com. We have $22.03 PT which if reached, will make NASDAQ:LOXO worth $42.67 million less.
Analysts await Loxo Oncology Inc (NASDAQ:LOXO) to report earnings on November, 8. They expect $-0.77 EPS, down 45.28% or $0.24 from last year’s $-0.53 per share. After $-0.77 actual EPS reported by Loxo Oncology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Loxo Oncology Inc (NASDAQ:LOXO) Ratings Coverage
Out of 3 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 2 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 67% are positive. Loxo Oncology Inc has been the topic of 11 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The stock of Loxo Oncology Inc (NASDAQ:LOXO) has “Buy” rating given on Wednesday, March 16 by Citigroup. The stock of Loxo Oncology Inc (NASDAQ:LOXO) has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. Citigroup initiated the stock with “Buy” rating in Friday, January 15 report. The company was maintained on Tuesday, August 4 by Oppenheimer. The firm has “Sell” rating given on Friday, August 28 by Zacks. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, March 16 report. On Thursday, August 27 the stock rating was maintained by Cowen & Co with “Outperform”. As per Monday, January 18, the company rating was initiated by Citigroup.
According to Zacks Investment Research, “Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.”
Insitutional Activity: The institutional sentiment increased to 2.82 in Q2 2016. Its up 1.46, from 1.36 in 2016Q1. The ratio increased, as 6 funds sold all Loxo Oncology Inc shares owned while 11 reduced positions. 12 funds bought stakes while 36 increased positions. They now own 20.32 million shares or 11.63% more from 18.21 million shares in 2016Q1.
Orbimed Advsr Limited Liability Corporation last reported 2.18 million shares in the company. Moreover, Vanguard Group Inc has 0% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 499,283 shares. Credit Suisse Ag last reported 10,509 shares in the company. The Connecticut-based Aqr Ltd Liability Com has invested 0% in Loxo Oncology Inc (NASDAQ:LOXO). New York State Common Retirement Fund holds 14,473 shares or 0% of its portfolio. Dafna Mngmt Limited Liability Corp accumulated 1.87% or 101,966 shares. Tiaa Cref Investment Management Limited Liability holds 39,326 shares or 0% of its portfolio. Deerfield Commerce last reported 0.23% of its portfolio in the stock. Northern Trust Corporation has 165,048 shares for 0% of their US portfolio. Glenmede Trust Na has invested 0% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO). Nationwide Fund Advisors holds 23,392 shares or 0% of its portfolio. Rs Inv Management Ltd Liability holds 0.36% or 1.51M shares in its portfolio. Alliancebernstein Lp has 0% invested in the company for 8,800 shares. Moreover, Bnp Paribas Arbitrage has 0% invested in Loxo Oncology Inc (NASDAQ:LOXO) for 554 shares. Awm Invest Company has invested 0.94% of its portfolio in Loxo Oncology Inc (NASDAQ:LOXO).
Insider Transactions: Since May 17, 2016, the stock had 1 insider purchase, and 4 sales for $19.97 million net activity. Bonita David P sold 447,857 shares worth $12.07M. Shares for $12.07 million were sold by ORBIMED ADVISORS LLC on Wednesday, August 10. On Thursday, August 11 Flaherty Keith T. sold $389,967 worth of the stock or 15,000 shares. $5.00 million worth of Loxo Oncology Inc (NASDAQ:LOXO) was bought by AISLING CAPITAL III LP.
More important recent Loxo Oncology Inc (NASDAQ:LOXO) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on August 01, 2014, also Globenewswire.com published article titled: “Loxo Oncology Announces Second Quarter 2016 Financial Results”, Quotes.Wsj.com published: “News Loxo Oncology Inc.LOXO” on August 01, 2014. More interesting news about Loxo Oncology Inc (NASDAQ:LOXO) was released by: Finance.Yahoo.com and their article: “Loxo Oncology to Present at Upcoming Investor Conferences” with publication date: September 01, 2016.
LOXO Company Profile
Loxo Oncology, Inc., incorporated on May 9, 2013, is a biopharmaceutical company. The Firm is engaged in the development of selective medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. LOXO-101 is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family that it is developing for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma and breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.